1-4 July 2020 - Elsevier Health

Aims and ScopeAnnals of Oncology, the journal of the European Society for Medical Oncologyand the Japanese Society of Medical Oncology, provides rapid and efficientpeer-review publications on innovative cancer treatments or translational workrelated to oncology and precision medicine.Main focuses of interest include: systemic anticancer therapy (with specificinterest on molecular targeted agents and new immune therapies), randomizedtrials (including negatives ones), top-level guidelines, and new fields currentlyemerging as key components of personalized medicine, such as molecularpathology, bioinformatics, modern statistics, and biotechnologies. Radiotherapy,surgery and pediatrics manuscripts can be considered if they display a clearinteraction with one of the fields above or are paradigm-shifting.With a large international editorial board of experts who are leaders in theirfields, Annals of Oncology aims at delivering the best communication on the fastmoving, and continually evolving, global oncology landscape.For a full and complete Guide for Authors, please go to www.annalsofoncology.orgAuthor inquiriesOnce a manuscript is submitted, you can follow manuscript developments fromyour online account, at the Annals of Oncology online submission websitehttp://mc.manuscriptcentral.com/annonc. You can track your accepted article athttp://www.elsevier.com/trackarticle. You are also welcome to contact Customer Support via http://support.elsevier.com.Publication InformationPublication information: Annals of Oncology (ISSN 0923-7534) comprises 12 issuesplus supplements in each volume, with volume 31 scheduled for 2020. Subscriptionprices are available upon request from the Publisher or from the Elsevier CustomerService Department nearest you or from this website (http://www.elsevier.com/locate/annonc). Subscriptions are accepted on a prepaid basis only and areentered on a calendar year basis. Issues are sent by standard mail (surface withinEurope, air delivery outside Europe). Priority rates are available upon request.USA mailing noticeAnnals of Oncology (ISSN 0923-7534) is published monthly by (Elsevier Ltd, TheBoulevard, Langford Lane, Kidlington, Oxford OX5 1GB, UK). USA POSTMASTER:Send change of address to Annals of Oncology, Elsevier, Journal Returns, 1799Highway 50 East, Linn, MO 65051, USA. AIRFREIGHT AND MAILING in USA by AirBusiness Ltd., c/o Worldnet Shipping Inc., 156-15, 146th Avenue, 2nd Floor,Jamaica, NY 11434, USA.Orders, claims, and journal inquiriesPlease visit our Support Hub page https://service.elsevier.com for assistance.AdvertisingIf you are interested in advertising or other commercial opportunities pleasevisit http://www.elsmediakits.comAdvertising orders and inquiries can be sent to: Europe and ROW: Sarah JaneEllis, Elsevier Ltd, 125 London Wall, London, EC2Y 5AS, United Kingdom; email:s.ellis@elsevier.com, 44 207 424 4538, USA, Canada and South America: BillHipple, Elsevier Inc., 230 Park Avenue, Suite 800, New York, NY 10169-0901,USA; email: b.hipple@elsevier.com, phone: ( 1) (212) 646-671-0385.ReprintsFor requests from industry and companies regarding bulk article reprints,translation opportunities for previously published material, and corporateonline opportunities, please email one of our sales team http://reprints.elsevier.com/contact or visit http://reprints.elsevier.com/solutionsJournal supplementsFor further information about opportunities with regard to Journal supplementissues, please email: Evelina Euren e.euren@elsevier.com or visit al-supplementsLanguage (usage and editing services)Please write your text in good English (American or British usage is accepted,but not a mixture of these). Authors who feel their English language manuscriptmay require editing to eliminate possible grammatical or spelling errors and toconform to correct scientific English may wish to use the English LanguageEditing service available from Elsevier’s WebShop http://webshop.elsevier.com/languageediting/ or visit our customer support site http://support.elsevier.comfor more information.Copyright Information The European Society for Medical Oncology 2020. Published by Elsevier Ltd.All rights reserved.This journal and the individual contributions contained in it are protected undercopyright, and the following terms and conditions apply to their use in additionto the terms of any Creative Commons or other user license that has beenapplied by the publisher to an individual article:Photocopying: Single photocopies of single articles may be made forpersonal use as allowed by national copyright laws. Permission is notrequired for photocopying of articles published under the CC BY license norfor photocopying for non-commercial purposes in accordance with any otheruser license applied by the publisher. Permission of the publisher and payment of a fee is required for all other photocopying, including multiple orsystematic copying, copying for advertising or promotional purposes, resale,and all forms of document delivery. Special rates are available for educationalinstitutions that wish to make photocopies for non-profit educational classroom use.Derivative Works: Users may reproduce tables of contents or prepare lists ofarticles including abstracts for internal circulation within their institutions orcompanies. Other than for articles published under the CC BY license, permission of the publisher is required for resale or distribution outside the subscribing institution or company.For any subscribed articles or articles published under a CC BY-NC-NDlicense, permission of the publisher is required for all other derivative works,including compilations and translations.Storage or Usage: Except as outlined above or as set out in the relevant userlicense, no part of this publication may be reproduced, stored in a retrievalsystem or transmitted in any form or by any means, electronic, mechanical,photocopying, recording or otherwise, without prior written permission of thepublisher.Permissions: For information on how to seek permission visit www.elsevier.com/permissions.Author rights: Author(s) may have additional rights in their articles as set outin their agreement with the publisher (more information at itioners and researchers must always rely on their own experience andknowledge in evaluating and using any information, methods, compounds orexperiments described herein. Because of rapid advances in the medical sciences, in particular, independent verification of diagnoses and drug dosagesshould be made. To the fullest extent of the law, no responsibility is assumed bythe publisher and European Society for Medical Oncology for any injury and/ordamage to persons or property as a matter of products liability, negligence orotherwise, or from any use or operation of any methods, products, instructionsor ideas contained in the material herein.Although all advertising material is expected to conform to ethical (medical)standards, inclusion in this publication does not constitute a guarantee orendorsement of the quality or value of such product or of the claims made of itby its manufacturer.Funding body agreements and policiesElsevier has established agreements and developed policies to allow authorswhose articles appear in journals published by Elsevier, to comply with potentialmanuscript archiving requirements as specified as conditions of their grantawards. To learn more about existing agreements and policies please visit http://www.elsevier.com/fundingbodies.The paper used in this publication meets the requirements of ANSI/NISOZ39.48-1992 (Permanence of Paper).Printed by Henry Ling Ltd, Dorchester, UK.

An Official Journal of the European Society for Medical Oncology and the Japanese Society of Medical OncologyVolume 31 j Supplement 3 j July 2020Abstract Book of ESMO 22nd World Congress on Gastrointestinal Cancer, 2020 Virtual1-4 July 2020AbstractsPostersPoster DiscussionsS89S212Note: Abstract suffixes“PD”“P”indicates a submitted abstract accepted for poster discussionindicates a submitted abstract accepted for poster presentation

POSTERSP-1LINC00184 promotes the stemness and chemoresistance of gastriccancer by interacting with YAP and by promoting exosomes-mediatedmacrophage M2 polarizationH. Piao, J. ZhangLiaoning Cancer Hospital, Shenyang, ChinaBackground: Long non-coding RNAs (lncRNAs) are involved in the pathology ofvarious tumors, including gastric cancer (GC). The crosstalk between tumor-associatedmacrophages (TAMs) and cancer cells in the tumor microenvironment promotes tumor development and confers chemoresistance, yet the contribution of lncRNAmediated crosstalk between TAMs and GC cells to tumor chemoresistance is not wellunderstood. In this study, we further investigated the underlying tumor-promotingroles of LINC00184 and as molecular mediators involved in these processes.Methods: GC cells and 165 GC tissue samples were involved in this study. Smallinterfering RNA (siRNA) sequences were used to knock down LINC00184. Cellapoptosis was measured by flow cytometry. SGC-7901 cells with H19 stably knockeddown were used to establish a xenograft model. The indicated protein levels inxenograft tumor tissues were confirmed by immunohistochemistry assay, and cellapoptosis was analyzed by TUNEL apoptosis assay. RNA-FISH and immunofluorescence assays were performed to assess the expression of LINC00184 in tumor stromaand cancer nests. The AldeRed ALDH detection assay was performed to detectintracellular aldehyde dehydrogenase (ALDH) enzyme activity. Isolated exosomeswere identified by transmission electron microscopy, nanoparticle tracking andWestern blotting.Results: LINC00184 was significantly up-regulated in GC tissues. And the LINC00184overexpression was associated with advanced TNM stages and poor prognosis.Moreover, LINC00184 was associated with the stemness of GC stem cells in GCspecimens. LINC00184 promoted the stemness of GC and the chemoresistance of GCcells in vitro and in vivo. Mechanistically, LINC00184 regulated the Hippo pathway viainteracting with YAP to prevent its phosphorylation. Furthermore, GC cell-derivedexosomes transported LINC00184 into macrophages which mediate macrophage M2polarization, thereby, in turn, promoting stemness and chemoresistance of GC cells. Inaddition, exosomal LINC00184 levels in blood plasma turned out to be higher intreatment-naive GC patients but lower after tumor resection. Compared to traditionaltumor markers (CEA, CA199), exosomal LINC00184 in GC plasma displayed a betterdiagnostic value.Conclusion: LINC00184 promoted the stemness and chemoresistance of GC byregulated Hippo pathway. Exosomal LINC00184 induced macrophage M2 polarization.Our results suggested that overexpression of LINC00184 was involved in the formation of tumor microenvironment and contributed to tumor chemoresistance.Legal entity responsible for the study: The author.Funding: Liaoning S&T Project (20180550999); Shenyang young and middle-agedscientific & technological innovation talents support plan (RC180199); National keyresearch and development program (K1818).Disclosure: The presenting author has declared no conflicts of 083P-2An update on the trends for hepatic cancer subtypes in thePhilippines, 2003-2012: A population-based studywere taken from the Philippines Statistics Authority (PSA), and each annual population from 2003 - 2012 was estimated using exponential function by extrapolation.Results: LC incidence showed increasing average annual rates in the past 10 years,among observed rates overall (10.94), men (15.53) and women (6.39). Among LChistological subtypes in carcinoma, hepatocellular contributed the highest rates inmen (15.19) and women (5.23), followed by unspecified carcinoma in men (1.73) andwomen (0.78). Incidence trend declined in both sexes and increased thereafter, inmen in 2007 (APC: 16.82, 95% CI: -5.70; 44.80) and women in 2008 (APC: 19.95, 95%CI: -21.7; 83.7). The highest increase in average annual percentage change (AAPC)among LC histological subtypes was observed to be hepatoblastoma in men (AAPC:4.91, 95% CI: -8.90; 20.80) and women (AAPC: 16.33, 95% CI: -0.60; 34.50). Cholangiocarcinoma also showed an increasing AAPC, in men (AAPC: 3.68, 95% CI: -7.90;16.70) and women (AAPC: 0.15, 95% CI: -14.1; 16.7). From the cohort 2003-2007 tocohort 2008-2012, unspecified malignant neoplasm eventually increased the averageannual rates by threefold, in men (4.10 to 12.05), and women (1.96 to 4.85).Conclusion: The study revealed that from 2003-2012, divergent LC trends by genderand histologic subtype were consistently increased. Male LC incidence annual rateswere observably higher compared with females. Among LC histological subtypes, anincrease in incidence was observed in hepatocellular carcinoma for the past 10-yearperiod. Targeted screening and treatment in hepatitis B virus (HBV) and hepatitis Cvirus (HCV), treatment of diabetes, and primary prevention of obesity will be thepossible solutions in reducing the increasing LC incidence.Acknowledgement: I would like to express my sincere gratitude to my advisor Prof.Jin Kyoung Oh for the continuous support of my M.P.H journey and related research,for her patience, motivation, and immense knowledge. Her guidance helped me in allthe time of research and writing of this study. Besides my advisor, I would like tothank the rest of my co-author Mr. Jayson Pasaol, M.P.H for his insightful commentsand encouragement, but also for the contributions which incented me to polish myresearch from various perspectives. My sincere thanks also goes to Dr. EdmundConcha, Dr. Rica Mirasol Lumague, ma’am Gehan Clerigo, and the rest of researchcommittee staff of Rizal Cancer Registry who provided me an opportunity to learnnew research ideas and who gave access to the Cancer Registry office and researchfacilities in the hospitals. Without their precious support, it would not be possible toconduct this research.Legal entity responsible for the study: The authors.Funding: Has not received any funding.Disclosure: The presenting author has declared no conflicts of 084P-3Features of metabolic profiles of blood serum and erythrocytemembranes associated with metastasis in colorectal cancerM. Kruchinina1, A. Gromov1, V. Kruchinin2, M. Shashkov3, A. Sokolova4, I. Yakovina5,N. Bannova51Research Institute of Internal and Preventive Medicine, Branch of the Institute ofCytology and Genetics, Siberian Branch of the Russian Academy of Sciences, Novosibirsk, Russia; 2Rzhanov Institute of Semiconductor Physics, Siberian Branch of RussianAcademy of Sciences, Novosibirsk, Russia; 3Boreskov Institute of Catalysis, SiberianBranch of Russian Academy of Sciences, Novosibirsk, Russia; 4Vorozhtsov Institute ofOrganic Chemistry, Siberian Branch of Russian Academy of Sciences, Novosibirsk,Ru

Elsevier has established agreements and developed policies to allow authors whose articles appear in journals published by Elsevier,to comply with potential manuscript archiving requirements as specified as conditions of their grant